logo
Hurricane forecasters are losing 3 key satellites ahead of peak storm season − a meteorologist explains why it matters

Hurricane forecasters are losing 3 key satellites ahead of peak storm season − a meteorologist explains why it matters

Yahoo02-07-2025
About 600 miles off the west coast of Africa, large clusters of thunderstorms begin organizing into tropical storms every hurricane season. They aren't yet in range of Hurricane Hunter flights, so forecasters at the National Hurricane Center rely on weather satellites to peer down on these storms and beam back information about their location, structure and intensity.
The satellite data helps meteorologists create weather forecasts that keep planes and ships safe and prepare countries for a potential hurricane landfall.
Now, meteorologists are about to lose access to three of those satellites.
On June 25, 2025, the Trump administration issued a service change notice announcing that the Defense Meteorological Satellite Program, DMSP, and the Navy's Fleet Numerical Meteorology and Oceanography Center would terminate data collection, processing and distribution of all DMSP data no later than June 30. The data termination was postponed until July 31 following a request from the head of NASA's Earth Science Division.
I am a meteorologist who studies lightning in hurricanes and helps train other meteorologists to monitor and forecast tropical cyclones. Here is how meteorologists use the DMSP data and why they are concerned about it going dark.
At its most basic, a weather satellite is a high-resolution digital camera in space that takes pictures of clouds in the atmosphere.
These are the satellite images you see on most TV weather broadcasts. They let meteorologists see the location and some details of a hurricane's structure, but only during daylight hours.
Meteorologists can use infrared satellite data, similar to a thermal imaging camera, at all hours of the day to find the coldest cloud-top temperatures, highlighting areas where the highest wind speeds and rainfall rates are found.
But while visible and infrared satellite imagery are valuable tools for hurricane forecasters, they provide only a basic picture of the storm. It's like a doctor diagnosing a patient after a visual exam and checking their temperature.
For more accurate diagnoses, meteorologists rely on the DMSP satellites.
The three satellites orbit Earth 14 times per day with special sensor microwave imager/sounder instruments, or SSMIS. These let meteorologists look inside the clouds, similar to how an MRI in a hospital looks inside a human body. With these instruments, meteorologists can pinpoint the storm's low-pressure center and identify signs of intensification.
Precisely locating the center of a hurricane improves forecasts of the storm's future track. This lets meteorologists produce more accurate hurricane watches, warnings and evacuations.
Hurricane track forecasts have improved by up to 75% since 1990. However, forecasting rapid intensification is still difficult, so the ability of DMPS data to identify signs of intensification is important.
About 80% of major hurricanes – those with wind speeds of at least 111 mph (179 kilometers per hour) – rapidly intensify at some point, ramping up the risks they pose to people and property on land. Finding out when storms are about to undergo intensification allows meteorologists to warn the public about these dangerous hurricanes.
NOAA's Office of Satellite and Product Operations described the reason for turning off the flow of data as a need to mitigate 'a significant cybersecurity risk.'
The three satellites have already operated for longer than planned.
The DMSP satellites were launched between 1999 and 2009 and were designed to last for five years. They have now been operating for more than 15 years. The United States Space Force recently concluded that the DMSP satellites would reach the end of their lives between 2023 and 2026, so the data would likely have gone dark soon.
Three other satellites in orbit – NOAA-20, NOAA-21 and Suomi NPP – have a microwave instrument known as the advanced technology microwave sounder.
The advanced technology microwave sounder, or ATMS, can provide data similar to the special sensor microwave imager/sounder, or SSMIS, but at a lower resolution. It provides a more washed-out view that is less useful than the SSMIS for pinpointing a storm's location or estimating its intensity.
The U.S. Space Force began using data from a new defense meteorology satellite, ML-1A, in late April 2025.
ML-1A is a microwave satellite that will help replace some of the DMSP satellites' capabilities. However, the government hasn't announced whether the ML-1A data will be available to forecasters, including those at the National Hurricane Center.
Satellite programs are planned over many years, even decades, and are very expensive. The current geostationary satellite program launched its first satellite in 2016 with plans to operate until 2038. Development of the planned successor for GOES-R began in 2019.
Similarly, plans for replacing the DMSP satellites have been underway since the early 2000s.
Delays in developing the satellite instruments and funding cuts caused the National Polar-orbiting Operational Environmental Satellite System and Defense Weather Satellite System to be canceled in 2010 and 2012 before any of their satellites could be launched.
The 2026 NOAA budget request includes an increase in funding for the next-generation geostationary satellite program, so it can be restructured to reuse spare parts from existing geostationary satellites. The budget also terminates contracts for ocean color, atmospheric composition and advanced lightning mapper instruments.
The 2025 Atlantic hurricane season, which runs from June 1 to Nov. 30, is forecast to be above average, with six to 10 hurricanes. The most active part of the season runs from the middle of August to the middle of October, after the DMSP satellite data is set to be turned off.
Hurricane forecasters will continue to use all available tools, including satellite, radar, weather balloon and dropsonde data, to monitor the tropics and issue hurricane forecasts. But the loss of satellite data, along with other cuts to data, funding and staffing, could ultimately put more lives at risk.
This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Chris Vagasky, University of Wisconsin-Madison
Read more:
Hurricane forecasts are more accurate than ever – NOAA funding cuts could change that, with a busy storm season coming
Forecasters expect a busy 2025 hurricane season – a storm scientist explains why and what meteorologists are watching
Hurricane hunters fly through extreme storms to forecast intensity – here's what happens when the plane plunges into the eyewall
Chris Vagasky is a member of the American Meteorological Society and the National Weather Association.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gabon forest cave reveals clues about prehistoric central Africa
Gabon forest cave reveals clues about prehistoric central Africa

Yahoo

time2 hours ago

  • Yahoo

Gabon forest cave reveals clues about prehistoric central Africa

In Gabon's sprawling forest, archaeologists dig for ancient clues that could unlock the secrets of how prehistoric humans lived and interacted in the changing landscape of central Africa. Two billion years ago, the eastern Gabonese region of Lastourville was covered by a vast ocean. But that has long given way to dense forest and dolomite cliffs dotted with caves, within which scientists have unearthed traces of human life dating back to 25,000 years BC. Off the beaten track even for archaeologists, the Youmbidi rock shelter, a cavern typical of those chosen by prehistoric humans to set up their homes, is the focus for French geoarchaeologist Richard Oslisly's team. Among their finds: a stone tool which could have been used for cutting or making fibres dating to before 10,000 BC. An arrowhead has also been unearthed, as has a collection of dolomite, quartz and jasper shards, cut up to 10,000 years ago by the cave's inhabitants. "The vast majority of research in Africa has taken place in open landscapes such as the Sahara, Sahel or Egypt," said Oslisly, who has spent 45 years working in central Africa. "They said to me 'there's nothing in the forest' (but) I took up the challenge of finding out what was happening there," he added. "We realise there is a very close relationship between man and nature in these forests, where people have lived for a very long time," Oslisly said. The Youmbidi cave -- where scientists have recorded 12,000 years of continuous human habitation -- is an enticing spot for the archeologists. "We don't know at all how these people lived, what their way of life was, what their names were, what their languages were," said Geoffroy de Saulieu from France's IRD Research Institute for Development. "Our research will help us to know a little more," he added. - Jigsaw puzzle - After a month of digging and careful sorting of every stone, charcoal remnant, bone and other treasure buried below the cave, the team has elements to help decipher the past. De Saulieu said it was like a jigsaw puzzle. "You have to... gather the smallest clues, place them end to end to gradually reconstruct a whole universe that has disappeared and which is, nevertheless, at the origin of the way of life in central Africa today," said the expert, currently attached to the National Agency of National Parks of Gabon. One of the oldest bits of pottery found in central Africa, which dated to more than 6,500 years ago, is among this year's finds. Human-looking teeth that could allow DNA to be extracted in what would prove a significant leap in research have also excited archaeologists. And, like all the artefacts, a bead likely made between 3,300 and 4,900 years ago from a snail shell also offers precious insight as a "very humble but beautiful witness" of the epoch in question. Dispelling stereotypical images of prehistoric Man, it suggests people had "real customs, a real civilisation and art of living," de Saulieu said. The pottery "shows that these societies weren't immobile, they had launched themselves into technical innovations", he added. The discoveries fan his fascination for the richness of "the social life which existed in the region's forests". - Resilience - Glimpses into an ancient lost world can also be useful for tackling present-day challenges, the experts said. During the Holocene period which dates back the past 12,000 years, "central Africa has experienced very significant changes in climate, hydrology and vegetation," said paleoclimatologist Yannick Garcin, also from the IRD and involved in the Youmbidi dig. The hope is that the cave will unlock an understanding of "the resilience of human populations in the past and how they were able to adapt to climate changes that could have been drastic", he said. Central Africa for that reason "deserves major development in terms of research", Oslisly argued. Understanding what happened in prehistoric times can help scientists today react to modern-day issues, he added. "Good studies on the relationship between Man and the environment in the past will allow us to react better to the environmental changes that are ahead of us," he said. lnf/hpn/kjm/cw

Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)

Yahoo

time3 hours ago

  • Yahoo

Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency (EMA) orphan drug designation, enabling readiness for initiation across sites in both the U.S. and Europe PS-002, Purespring's lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathy and is supported by a wealth of preclinical data London – 5 August 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that its UK Clinical Trial Application (CTA) for a planned Phase I/II study of PS-002, Purespring's lead programme, in patients with IgA nephropathy (IgAN) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the NHS Health Research Authority (HRA) and Research Ethics Committee (REC). 'The CTA approval for our Phase I/II clinical trial of PS-002 represents another key milestone as we complete our transition to a clinical-stage precision nephrology company,' said Haseeb Ahmad, Purespring's Chief Executive Officer. 'Building on the recent FDA IND clearance and EMA orphan drug designation, this further validates the potential of our podocyte-targeting approach to go beyond symptom management and directly target kidney disease at its source. Looking ahead, we are committed to working closely with regulators and sites across the U.S. and Europe with the view to expand the therapeutic options available for people living with IgAN.' PS-002 was developed to target the underlying cause of many kidney diseases by modulating complement activation in the kidney via precision targeting of podocytes. The programme is initially focused on the treatment of IgA nephropathy (IgAN), a rare and chronic autoimmune kidney disease that primarily affects young adults. In IgAN, aberrant immunoglobin A (IgA) protein becomes trapped in the kidney's filters, known as the glomeruli, causing complement activation, inflammation, damage and scarring. A significant proportion of affected patients will go on to develop kidney failure despite currently available therapies. The Phase I/II clinical trial, which is expected to enroll its first patient in Q4 2025, will evaluate local administration of PS-002 to treat IgAN. In the Phase 1 part of the Phase I/II study, the main read-outs will be safety parameters, which, together with efficacy biomarkers, will be leveraged to select a dose for the Phase 2 part of the study. This second phase will be used to further define the safety profile and provide early markers of efficacy. Enabled by this latest regulatory approval and the recent U.S. IND clearance, as announced in July 2025, the Phase I/II study will recruit patients across the U.S. and Europe. For further information, contact: Purespring: Peter Mulcahycontact@ (0)20 3855 6324LinkedIn ICR Healthcare Amber Fennell, Sarah Elton-Farrpurespring@ Notes to Editors About Purespring Purespring is developing therapies to halt or prevent kidney disease, one of humankind's most poorly treated disease areas. Founded on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, Purespring is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell that is implicated in the majority of renal disease. Purespring's platform approach enables streamlined gene therapy development for both acquired and genetic renal diseases, offering the potential to halt, reverse and even cure both rare and common kidney diseases. The Company currently has a pipeline of programmes in development including the lead asset for treatment of IgA Nephropathy (IgAN) and other complement mediated kidney disease. The Company also has programmes for disease caused by mutations in the gene NPHS2, as well as other monogenic glomerular kidney diseases. Based in London, the Purespring team combines world-leading expertise in podocyte biology and kidney disease with a wealth of experience in gene therapies, anchored in a culture of diversity, creativity and delivery. Purespring is backed by leading biotech investors, including Syncona Limited, Sofinnova Partners, Gilde Healthcare, Forbion, and the British Business Bank and has raised £115m ($149m) to date. For more information please visit: and follow us on in to access your portfolio

Does Chemoradiation Up Second Cancer Risk in Rectal Cancer?
Does Chemoradiation Up Second Cancer Risk in Rectal Cancer?

Medscape

time4 hours ago

  • Medscape

Does Chemoradiation Up Second Cancer Risk in Rectal Cancer?

TOPLINE: Among patients with locally advanced rectal cancer, concurrent chemoradiotherapy did not significantly increase second pelvic malignancies compared to chemotherapy alone, but it did raise the risk for nonpelvic cancers. METHODOLOGY: The risk for second cancers after pelvic radiation in patients with locally advanced rectal cancer is unclear, with recent studies yielding conflicting results. To better understand the risk for second malignancies, researchers evaluated 2624 patients with stage II or III rectal cancer who received chemotherapy alone (n = 460) or radiation therapy concurrent with chemotherapy (chemoradiotherapy; n = 2164) between January 1995 and October 2019. Researchers analyzed the cumulative incidence of second malignancies, defined as a new cancer diagnosed more than 2 years after the initial rectal cancer diagnosis. Patients received adjuvant chemotherapy regimens, including FOLFOX (60%), 5-fluorouracil (32%), and capecitabine and oxaliplatin (4%), with median radiation prescription doses of 5040 centigrays for conventional treatments and 5000 centigrays for intensity-modulated radiation therapy. The median follow-up was 6.5 years in the concurrent chemoradiotherapy cohort and 5.6 years in the chemotherapy-alone cohort. TAKEAWAY: Rates of second pelvic malignancies at 10 years were higher with chemoradiotherapy versus chemotherapy, but the differences were not significant: The 10-year cumulative incidence was 5.8% with chemoradiotherapy vs 4.2% with chemotherapy (P = .30). Overall, the most common second pelvic malignancies were prostate adenocarcinoma (31%), bladder cancer (31%), and uterine cancer (28%). The 10-year incidence of second nonpelvic malignancies was significantly higher with chemoradiotherapy: 11% vs 4.4% with chemotherapy alone (P = .017). Overall, the most common second nonpelvic malignancies were lung cancer (24%), breast cancer (15%), and hematologic malignancies (13%). Compared with conventional radiation therapy, intensity-modulated radiation therapy and volumetric modulated arc therapy were associated with a reduced risk for second pelvic malignancies (P = .014). Several factors appeared to impact the risk for second malignancies following treatment. Adults aged 50 and older had higher risks for second pelvic (hazard ratio [HR], 3.03; P = .005) and nonpelvic (HR, 2.48; P < .001) malignancies. Diabetes was linked to an increased risk for second nonpelvic malignancies (HR, 1.51; P = .028), whereas tobacco abstinence was associated with a decreased risk (HR, 0.63; P = .013). IN PRACTICE: O verall, patients who received chemoradiotherapy had a significantly higher cumulative incidence of developing second cancers outside the pelvis but not within the pelvis, the authors concluded. However, 'the concern for radiation-induced second malignancies should not preclude from using [chemoradiotherapy]' in this patient population. Instead, 'these data serve as a foundation for future prospective studies evaluating ways to further reduce the risk of second malignancies in high-risk patients undergoing [chemoradiotherapy] for rectal cancer.' SOURCE: The study, led by Kathryn R. Tringale, MD, and Kush H. Patel of Memorial Sloan Kettering Cancer Center, New York City, was published online in the International Journal of Radiation Oncology, Biology, Physics. LIMITATIONS: Potential surveillance bias existed because patients who received concurrent chemoradiotherapy had more intensive follow-up than those who received chemotherapy alone. Median follow-up was short, and the retrospective design precluded comparing doses in organs at risk that developed second cancers with those that did not. DISCLOSURES: The study was partly funded by a National Institutes of Health/National Cancer Institute grant. Some authors reported receiving research funding and having other ties with various sources. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store